These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. Yazdi AS; Ghoreschi K; Sander CA; Röcken M Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766 [TBL] [Abstract][Full Text] [Related]
43. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. Sullivan RJ; Lawrence DP; Wargo JA; Oh KS; Gonzalez RG; Piris A N Engl J Med; 2013 Jul; 369(2):173-83. PubMed ID: 23841733 [No Abstract] [Full Text] [Related]
44. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978 [TBL] [Abstract][Full Text] [Related]
46. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. Falanga A; Marchetti M; Massi D; Merelli B; Verzeroli C; Russo L; Rulli E; Tondini C; Legramandi L; Nassini R; Scatena C; De Logu F; Cattaneo L; Mandalà M J Am Acad Dermatol; 2016 Jun; 74(6):1254-1256.e4. PubMed ID: 27185428 [No Abstract] [Full Text] [Related]
47. Melanoma BRAF fusions--response. Hutchinson KE; Ross JS; Stephens PJ; Miller VA; Sosman JA; Pao W Clin Cancer Res; 2014 Dec; 20(24):6632. PubMed ID: 25512636 [No Abstract] [Full Text] [Related]
48. [Gene abnormalities in melanoma and signal transduction antagonists]. Takada M Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754 [No Abstract] [Full Text] [Related]
49. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881 [TBL] [Abstract][Full Text] [Related]
50. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Yamaguchi M; Harada K; Ando N; Kawamura T; Shibagaki N; Shimada S Clin Exp Dermatol; 2011 Mar; 36(2):174-7. PubMed ID: 20545949 [TBL] [Abstract][Full Text] [Related]
52. The evolving universe of BRAF mutations in melanoma. Schaider H; Sturm RA Br J Dermatol; 2017 Oct; 177(4):893. PubMed ID: 29052896 [No Abstract] [Full Text] [Related]
53. Balloon cell melanoma possessed the ability to develop BRAF V600E mutation in cancer cells. Chen YY; Lan CE; Yen MC; Cheng ST Kaohsiung J Med Sci; 2021 Feb; 37(2):154-155. PubMed ID: 33118306 [No Abstract] [Full Text] [Related]
54. The pathway ahead in melanoma trials. Miller AJ; Markovic SN; Haluska P Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690 [No Abstract] [Full Text] [Related]
55. What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing. Wilson MA; Morrissette JJ; McGettigan S; Roth D; Elder D; Schuchter LM; Daber RD Cancer Genet; 2014 Jun; 207(6):272-5. PubMed ID: 25178945 [TBL] [Abstract][Full Text] [Related]
56. Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report. Ventura A; Pitocco R; Di Stefani A; Cota C; Spallone D; Bianchi L; Spallone G Br J Dermatol; 2019 May; 180(5):e142. PubMed ID: 31025747 [No Abstract] [Full Text] [Related]